On July 26, 2019, the Health and Global Policy Institute (HGPI) hosted a preparatory meeting to plan advocacy activities for AMR Alliance Japan.

Every year, approximately 700,000 people are estimated to die from antimicrobial resistance (AMR) related causes, and action is underway around the world to prevent that from happening. 

Sensing growing concern about AMR domestically and abroad, HGPI has taken the initiative to host multiple expert meetings on this subject since 2016. Over the course of those expert meetings, it was suggested that the establishment of an independent platform for multi-stakeholder discussion was needed to encourage more impactful collaborations on AMR policies. To that end, in November 2018, HGPI joined together with eight Japanese medical societies*1 involved with infectious disease medicine to create AMR Alliance Japan, a multi-stakeholder, collaborative body that will work to improve public health by promoting AMR countermeasures.

The Alliance continues discussions on how Japan can advance the fight against AMR domestically and lead on AMR policies globally. This meeting was held to discuss advocacy plans to be implemented after the announcement of recent policy recommendations by AMR Alliance Japan, as well as to clarify the way forward for the Alliance.

*1 The Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, the Japanese Society for Clinical Microbiology, the Japanese Society for Infection Prevention and Control, the Pharmaceutical Society of Japan, the Japanese Society of Pharmaceutical Healthcare and Sciences, the Japanese Society of Therapeutic Drug Monitoring, the Japanese Society for Medical Mycology

Participants: AMR Alliance Japan academic society members and corporate stakeholders

Roundtable Discussion
Roundtable Speakers (alphabetical order by last name)

Kyoko Ama (Representative, Ippan Shadan Hojin Shiro Shoni Iryo Mamoro Kodomo-tachi no Kai)
Midori Hirai (Chair, Pharmaceutical Education Committee, The Pharmaceutical Society of Japan / Director, Japanese Red Cross Hyogo Blood Center)
Hiroshi Kiyota (President, Japanese Society of Chemotherapy / Professor, Department of Urology, The Jikei University Katsushika Medical Center)
Yuichi Muraki (Representative, Japanese Society of Pharmaceutical Health Care and Sciences / Professor, Department of Clinical Pharmacoepidemiology, Kyoto Pharmaceutical University)
Shinya Nagase (Director, Diagnostic Systems, BD Life Sciences, Nippon Becton Dickinson Company, Ltd.)
Kazunobu Ouchi (President, Japanese Society for Pediatric Infectious Diseases / Professor, School of medicine, Kawasaki Medical University)
Akio Ozaki (Director, Public and Industry Policy, Health Policy, MSD K. K.)
Takuko Sawada (Director of the Board, Executive Vice President, Shionogi & Co., Ltd.)
Kazutoshi Shibuya (President, The Japanese Society for Medical Mycology / Professor, Department of Surgical Pathology, Toho University)
Kazuhiro Tateda (President, The Japanese Association for Infectious Diseases / President, The Japanese Society for Clinical Microbiology / Professor, Department of Microbiology and Infectious Diseases, Toho University)
Yasunori Tawaragi (Director, International Affairs, Japan Pharmaceutical Manufacturers Association)
Masaki Yoshida (President, Japanese Society for Infection Prevention and Control / Professor, Department of Infectious Disease and Infection Control, The Jikei University School of Medicine)

Moderator
Tomohito Shibata (Senior Associate, HGPI)